Frontage expands site to accommodate nicotine-related studies, develops assay portfolio

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Rattankun Thongbun)
(Image: Getty/Rattankun Thongbun)

Related tags: Frontage Laboratories, Clinical trials, CRO

Frontage Clinical Services has expanded its site in New Jersey to accommodate nicotine-related studies and is developing a portfolio of assays to evaluate tobacco-specific biomarkers.

Frontage Clinical Services, an associate of the contract research organization (CRO) Frontage Laboratories, has renovated its Secaucus, New Jersey-based site to accommodate tobacco and nicotine-related studies.

“Specialized clinical facilities are needed to control the ventilation in the areas that subjects are allowed to use combustible cigarettes or electronic nicotine delivery systems,” ​explained Gary Steidl, RPh, vice president, Frontage Clinical Services. “Controlling this area allows for blood samples to be collected effectively, even as the subjects continue to use the various devices.”

As part of the expansion, the company has added two dedicated negative-pressure rooms that use displacement ventilation. This enables participants to use various investigational tobacco products, including combustible cigarettes and electronic nicotine delivery systems (ENDS), as well as smoking cessation therapies, according to Frontage.

“These studies are part of addressing an important public health concern related to subjects who use tobacco and other nicotine-containing products.

“It is well known that there are significant health concerns with the use of combustible cigarettes, evaluating new ENDS products or nicotine replacement therapies can help provide alternatives to those who continue to use cigarettes,”​ Steidl told us.

In addition to the site expansion, Frontage Labs’ bioanalytical lab is developing an assay portfolio to evaluate tobacco-specific biomarkers of exposure and potential harm.

Additionally, the company last year acquired Concord Biosciences​, a preclinical CRO located on a 20-acre campus near Cleveland, OH. The company conducts drug safety, metabolism, bioanalytical, residue and environmental fate studies.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more